PTC Therapeutics Withdraws Translarna NDA for Duchenne Muscular Dystrophy Following FDA Feedback
核心洞察
PTC Therapeutics has withdrawn its New Drug Application resubmission for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy (搜索) after FDA indicated the data unlikely meets effectiveness thresholds.
The FDA shared that based on its review, the NDA submission data are unlikely to meet the Agency's threshold of substantial evidence of effectiveness to support approval.
This withdrawal represents a significant setback for treating boys and young men with nonsense mutation DMD in the U.S. after over two decades of development efforts.
PTC Therapeutics announced on February 12, 2026, that it has withdrawn the New Drug Application (NDA) resubmission for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (搜索) (DMD) following negative feedback from the U.S. Food and Drug Administration. The FDA indicated that the data in the submission are unlikely to meet the Agency's threshold of substantial evidence of effectiveness required for approval.
FDA Review Outcome
"FDA shared that based on its review to date, the data in the NDA submission are unlikely to meet the Agency's threshold of substantial evidence of effectiveness to support approval of Translarna," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "We have therefore made the decision to withdraw the NDA submission."
Klein expressed disappointment with the outcome, noting that the company has "worked tirelessly for over two decades to develop a safe and effective therapy for boys and young men affected by nonsense mutation DMD in the U.S. and are disappointed that FDA approval cannot be achieved."
About Translarna
Translarna (ataluren) is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin (搜索) in Duchenne muscular dystrophy (搜索).
Disease Background
Duchenne muscular dystrophy (搜索) is a rare and fatal genetic disorder that primarily affects males, resulting in progressive muscle weakness from early childhood and leading to premature death in the mid-20s due to heart and respiratory failure. The condition is a progressive muscle disorder caused by the lack of functional dystrophin (搜索) protein, which is critical to the structural stability of all muscles, including skeletal, diaphragm, and heart muscles.
Patients with Duchenne can lose the ability to walk as early as 10 years old, followed by loss of the use of their arms. Duchenne patients subsequently experience life-threatening lung complications, requiring the need for ventilation support, and heart complications in their late teens and 20s.
Regulatory Impact
This withdrawal represents a significant setback for PTC Therapeutics' efforts to bring Translarna to the U.S. market for treating nonsense mutation DMD. The company noted concerns about maintaining marketing authorization of Translarna in other geographies where it has been approved, as well as potential effects on other regulatory bodies following the U.S. withdrawal.